A buprenorphine/naloxone combination was launched on the EU market in 2006 as an alternative to buprenorphine alone, with the aim of reducing the potential and attractiveness for injecting use.
En kombination af buprenorphin/naloxon blev lanceret på markedet i EU i 2006 som et alternativ til buprenorphin alene og med det formål at nedbringe muligheden for og ønsket om at injicere det.